<DOC>
	<DOCNO>NCT02980198</DOCNO>
	<brief_summary>This study Proof Concept study aim evaluate production anti-IFNα antibody ( immune response ) adult subject dermatomyositis</brief_summary>
	<brief_title>Study IFN-K Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<criteria>Patient newly diagnose relapse `` definite '' `` probable '' dermatomyositis base ENMC criterion ( 2004 ) Patient MMT8 ≤ 120 and/or MMT5 ≤ 22 Patient require corticosteroid ( CS ) dose 1 mg/Kg ≤ 70 mg prednisone equivalent/day currently receive CS dose 1 mg/Kg ≤ 70 mg prednisone equivalent/day Is male female , age 18 65 year , inclusive , time screen visit Is highrisk human papilloma virus ( HPV ) positive ( RTqPCR ) cervical swab Has cytological abnormality ≥ HSIL cervical swab Is positive autoantibody antiNXP2 , TIF1ɤ , MDA5 antisynthetase antibody Is positive malignancy history malignancy Has receive IV pulse dose CS ( ≥ 250 mg prednisone equivalent/day ) Has receive intravenous immunoglobulin ( IVIg ) Has receive potent immunosuppressive drug cyclophosphamide , methotrexate , azathioprine , mycophenolate , cyclosporine A , oral tacrolimus Has receive abatacept , anifrolumab , belimumab , TNF antagonists another registered investigational biological therapy Has receive antiBcell therapy ( e.g . rituximab , epratuzumab ) Has receive live vaccine Has use investigational nonregistered product , investigational nonregistered vaccine Has inflammatory joint skin disease dermatomyositis may interfere study assessment Has frequent recurrence oral genital herpes simplex lesion Is high risk significant infection and/or current sign symptom infection entry receive intravenous antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>